Pretreatment with GPR88 Agonist Attenuates Postischemic Brain Injury in a Stroke Mouse Model
GPR88 효현제의 전처리에 의한 뇌졸중후 뇌손상 감소효과 연구
- Document Type
- Publications · Journal Article
- Registered DB
- KCI
- Journal
- 생명과학회지30(11) · pp.939 · 2020
- Citation
- KCI 0
- ISSN
- 1225-9918
Authors
- 이세원First author원광대학교
- Park, Jung Hwa부산대학교
- Kim, Min Jae부산대학교
- Choi, Byung Tae부산대학교
- Shin, Hwa-kyoungCorresponding author부산대학교
Abstract
Stroke is one of the leading causes of neurological disability worldwide and stroke patients exhibit a range of motor, cognitive, and psychiatric impairments. GPR88 is an orphan G protein-coupled receptor (GPCR) that is highly expressed in striatal medium spiny neurons; its deletion results in poor motor coordination and motor learning. There are currently no studies on the involvement of GPR88 in stroke or in post-stroke brain function recovery. In this study, we found a decrease in GPR88 protein and mRNA expression levels in an ischemic mouse model using Western blot and real-time PCR, respectively. In addition, we observed that, among the three types of cells derived from the brain (brain microvascular endothelial cells, BV2 microglial cells, and HT22 hippocampal neuronal cells), the expression of GPR88 was highest in HT22 neuronal cells, and that GPR88 expression was downregulated in HT22 cells under oxygen-glucose deprivation (OGD) conditions. Moreover, pretreatment with RTI- 13951-33 (10 mg/kg), a brain-penetrant GPR88 agonist, ameliorated brain injury following ischemia, as evidenced by improvements in infarct volume, vestibular-motor function, and neurological score. Collectively, our results suggest that GPR88 could be a potential drug target for the treatment of central nervous system (CNS) diseases, including ischemic stroke.
Keywords
Identifiers
- KCI
- ART002650496



Login
Back to Publication list